Longer Use of Alzheimer’s Drug May Help Patients

Continued Treatment With Aricept Shows Some Merit

Medically Reviewed by Michael W. Smith, MD on March 07, 2012
From the WebMD Archives

March 7, 2012 -- The Alzheimer’s drug Aricept helps people with early to moderate signs of the disease maintain a higher level of function, but just how long the drug continues working is not fully understood. A new study may help clear up some confusion.

Aricept is the most widely prescribed medication in a class of Alzheimer’s drugs known as cholinesterase inhibitors. Close to 50% of people stop taking it within a year because of side effects such as weight loss, agitation, and fainting, or because they no longer see any improvements in their mental abilities.

This raises the question of when to stop and what to do next.

Now a new study may provide some much-needed clarity. Aricept can remain effective into the later stages of Alzheimer’s. Adding another drug called Namenda does little to improve these results, even though the combination is common practice.

On its own, however, Namenda may provide some benefits, according to the research. Namenda works on the brain differently than Aricept does. Still, the main goal of this research was to focus more on Aricept’s effectiveness than Namenda’s.

And in the study, those people who stayed on Aricept did better than those who stopped taking it. They scored higher on standard tests measuring their mental ability and also were better able to perform activities of daily living.

These improvements, however, faded in the later stages of Alzheimer’s.

“The findings are illuminating and this affirms how most of us practice in the U.S.,” says Anton Porsteinsson, MD. He is the William and Sheila KonarProfessor of Psychiatry at the University of Rochester Medical Center in Rochester, N.Y.

“When should we stop?” is a question that comes up often from caregivers and loved ones of people with Alzheimer’s disease who are being treated with Aricept and other Alzheimer’s medicines. “We have this discussion on a regular basis with our patients,” Porsteinsson says.

What to Do Next? Treating Late-Stage Alzheimer’s Disease

Up until now, there was little evidence to support staying on Aricept. “If you stop treatment, they do worse,” he says. ”This substantiates that if someone is doing OK on Aricept and has no side effects, it makes sense to continue.”

And if they do stop Aricept, Namenda is still an option.

“Ongoing treatment matters,” Porsteinsson says.

Does this mean a person with Alzheimer’s will remain independent for longer? It is too soon to say that, Porsteinsson tells WebMD. “What it means is that you stay at a higher level of [mental] function longer. This study didn’t say whether it will keep you out of a nursing home.”

Better Therapies Needed ASAP

Peter Davies, PhD, is less enthusiastic about ongoing treatment for Alzheimer’s disease. He is the scientific director of the Litwin-Zucker Center for Research in Alzheimer’s Disease and Memory Disorders at The Feinstein Institute for Medical Research in Manhasset, N.Y.

“Continuing patients on Aricept once they've reached a fairly low level of [mental] function had some benefit, but this improvement was generally small in relation to the overall decline,” says Davies via email. “Those on the drug did a little better, but the overall decline continued. The bottom line here is that these drugs don't do a whole lot.”

William Thies, PhD, is the chief medical and scientific officer of the Alzheimer’s Association. He says the results are not all that surprising. “Certainly, it reinforces the need for more research to create better therapies that have larger effects on the disease than both [Aricept and Namenda],” he says via email. “The resounding message from the quite modest benefits seen in the treatments tested in this study is that we desperately need better treatments for Alzheimer’s; treatments with much larger benefits for those who take them; treatments that slow or stop the progression of the disease.”

“People with Alzheimer’s and their caregivers should be in regular communication with their doctors about the risks and benefits of the currently approved Alzheimer’s medications,” Thies says.

The study findings appear in the New England Journal of Medicine.

Show Sources


William Thies, PhD, chief medical and scientific officer, Alzheimer’s Association. 

Peter Davies, PhD, scientific director, Litwin-Zucker Center for Research on Alzheimer’s Disease, The Feinstein Institute for Medical Research, Manhasset, N.Y.

Anton Porsteinsson, MD, William and Sheila KonarProfessor of Psychiatry, University of Rochester Medical Center,  Rochester, N.Y.

Howard, R. New England Journal of Medicine, 2012.

Schneider, L.S. New England Journal of Medicine, 2012.

Alzheimer’s Association: “Alzheimer’s Facts and Figures.”

© 2012 WebMD, LLC. All rights reserved. View privacy policy and trust info